SaponiQx https://validator.w3.org/feed/docs/rss2.html Test Pipeline Hello world! SaponiQx and InvivoGen Announce Agreement for SaponiQx to Supply Cultured Plant Cell QS-21 Adjuvant SaponiQx, Probius, and Ginkgo Bioworks Unite to Revolutionize Vaccine Adjuvant Development What We Do SaponiQx and InvivoGen Launch STIMULON Cultured Plant Cell QS-21 Adjuvant for Commercial Purchase Chemical and biological characterization of vaccine adjuvant QS-21 produced via plant cell culture Plant Cell Culture-Derived Saponin Adjuvant Enhances Immune Response Against a Stabilized Human Metapneumovirus Pre-Fusion Vaccine Candidate In The News Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design Protected: test Who We Are QS-21 SaponiQx Announces Breakthrough in Scaling Up of STIMULON™ Cultured Plant Cell Adjuvant Protected: Pipeline – Copy Jennifer Wipf SaponiQx Advances Vaccine Development With the Availability of cGMP QS-21 From Its Proprietary Cultured Plant Cell Source Perspectives on World Immunization Day 2023 sample post New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks Al Dadson Contact Us SaponiQx Publishes Breakthrough on Scalable, Stable QS-21 Adjuvant Production for Pandemic Vaccine Development QS-7 QS-X Nathalie Garçon Brian Corvese Watch SaponiQx Presentation at Ginko Ferment Conference, 2023 sample post 2 sample post 3 Garo Armen SaponiQx joins Medical CBRN Defense Consortium James Embree Keith Flood Thomas Roper Susan Skinner Cynthia Gronostajski sample post 4 US FDA Advisory Committee votes to support effectiveness and safety of GSK’s respiratory syncytial virus older adult vaccine candidate sample post 5 Privacy Policy Home